This study will examine the effect is of 21-days intranasal Oxytocin on clinical symptoms and social function in these patients, in a double blind (treatment/placebo) study design.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
PTSD patients (DSM-IV criteria)
Ability to provide written informed consent
You may not be if
Suicidality
Psychosis
Borderline Personality
Arrhythmia
Cardiac disease (arrythmia, heart failure)
Hyponatremia
Hypertension
Severe renal insufficiency
Liver cirrhosis
Lactating or pregnant women, or undergoing fertility treatment
Clareo Health | The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)
